ArticleFrontiers in oncology2021

COL5A1 Serves as a Biomarker of Tumor Progression and Poor Prognosis and May Be a Potential Therapeutic Target in Gliomas.

Sujie Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.